S&P 500   4,502.27 (-1.63%)
DOW   34,327.75 (-0.90%)
QQQ   380.08 (-2.52%)
AAPL   160.24 (-2.15%)
MSFT   320.30 (-2.79%)
FB   303.32 (-2.28%)
GOOGL   2,818.47 (-1.43%)
AMZN   3,355.20 (-2.39%)
TSLA   1,011.46 (-6.74%)
NVDA   303.11 (-5.65%)
BABA   112.24 (-8.00%)
NIO   31.81 (-12.13%)
CGC   9.96 (-3.86%)
AMD   141.73 (-5.94%)
GE   91.93 (-3.47%)
MU   81.04 (-2.22%)
T   23.37 (+1.39%)
F   19.02 (-4.28%)
DIS   144.69 (-1.71%)
PFE   54.22 (+2.22%)
AMC   25.57 (-15.55%)
ACB   5.76 (-6.19%)
BA   196.06 (-3.12%)
S&P 500   4,502.27 (-1.63%)
DOW   34,327.75 (-0.90%)
QQQ   380.08 (-2.52%)
AAPL   160.24 (-2.15%)
MSFT   320.30 (-2.79%)
FB   303.32 (-2.28%)
GOOGL   2,818.47 (-1.43%)
AMZN   3,355.20 (-2.39%)
TSLA   1,011.46 (-6.74%)
NVDA   303.11 (-5.65%)
BABA   112.24 (-8.00%)
NIO   31.81 (-12.13%)
CGC   9.96 (-3.86%)
AMD   141.73 (-5.94%)
GE   91.93 (-3.47%)
MU   81.04 (-2.22%)
T   23.37 (+1.39%)
F   19.02 (-4.28%)
DIS   144.69 (-1.71%)
PFE   54.22 (+2.22%)
AMC   25.57 (-15.55%)
ACB   5.76 (-6.19%)
BA   196.06 (-3.12%)
S&P 500   4,502.27 (-1.63%)
DOW   34,327.75 (-0.90%)
QQQ   380.08 (-2.52%)
AAPL   160.24 (-2.15%)
MSFT   320.30 (-2.79%)
FB   303.32 (-2.28%)
GOOGL   2,818.47 (-1.43%)
AMZN   3,355.20 (-2.39%)
TSLA   1,011.46 (-6.74%)
NVDA   303.11 (-5.65%)
BABA   112.24 (-8.00%)
NIO   31.81 (-12.13%)
CGC   9.96 (-3.86%)
AMD   141.73 (-5.94%)
GE   91.93 (-3.47%)
MU   81.04 (-2.22%)
T   23.37 (+1.39%)
F   19.02 (-4.28%)
DIS   144.69 (-1.71%)
PFE   54.22 (+2.22%)
AMC   25.57 (-15.55%)
ACB   5.76 (-6.19%)
BA   196.06 (-3.12%)
S&P 500   4,502.27 (-1.63%)
DOW   34,327.75 (-0.90%)
QQQ   380.08 (-2.52%)
AAPL   160.24 (-2.15%)
MSFT   320.30 (-2.79%)
FB   303.32 (-2.28%)
GOOGL   2,818.47 (-1.43%)
AMZN   3,355.20 (-2.39%)
TSLA   1,011.46 (-6.74%)
NVDA   303.11 (-5.65%)
BABA   112.24 (-8.00%)
NIO   31.81 (-12.13%)
CGC   9.96 (-3.86%)
AMD   141.73 (-5.94%)
GE   91.93 (-3.47%)
MU   81.04 (-2.22%)
T   23.37 (+1.39%)
F   19.02 (-4.28%)
DIS   144.69 (-1.71%)
PFE   54.22 (+2.22%)
AMC   25.57 (-15.55%)
ACB   5.76 (-6.19%)
BA   196.06 (-3.12%)
NASDAQ:RUBY

Rubius Therapeutics Stock Competitors

$12.10
-0.51 (-4.04%)
(As of 12/3/2021 02:58 PM ET)
Add
Compare
Today's Range
$12.01
$12.56
50-Day Range
$11.86
$19.05
52-Week Range
$6.21
$38.71
Volume
12,298 shs
Average Volume
809,525 shs
Market Capitalization
$1.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.38

Rubius Therapeutics (NASDAQ:RUBY) Vs. TWST, ADPT, SWTX, SANA, RLAY, RXRX, VALN, KYMR, IOVA, and TIL

Should you be buying Rubius Therapeutics stock or one of its competitors? The main competitors of Rubius Therapeutics include Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), SpringWorks Therapeutics (SWTX), Sana Biotechnology (SANA), Relay Therapeutics (RLAY), Recursion Pharmaceuticals (RXRX), Valneva (VALN), Kymera Therapeutics (KYMR), Iovance Biotherapeutics (IOVA), and Instil Bio (TIL). These companies are all part of the "biological products, except diagnostic" industry.

Rubius Therapeutics vs.

Adaptive Biotechnologies (NASDAQ:ADPT) and Rubius Therapeutics (NASDAQ:RUBY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.

Adaptive Biotechnologies currently has a consensus target price of $60.33, suggesting a potential upside of 137.07%. Rubius Therapeutics has a consensus target price of $26.33, suggesting a potential upside of 114.79%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Adaptive Biotechnologies is more favorable than Rubius Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptive Biotechnologies
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Rubius Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Adaptive Biotechnologies has higher revenue and earnings than Rubius Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$98.38 million36.18-$146.23 million-$1.37-18.41
Rubius TherapeuticsN/AN/A-$167.73 million-$2.12-5.71

Rubius Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -129.89%. Adaptive Biotechnologies' return on equity of -27.07% beat Rubius Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Adaptive Biotechnologies -129.89% -27.07% -18.07%
Rubius Therapeutics N/A -78.24% -49.71%

Adaptive Biotechnologies has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Rubius Therapeutics has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500.

In the previous week, Adaptive Biotechnologies and Adaptive Biotechnologies both had 3 articles in the media. Rubius Therapeutics' average media sentiment score of 0.30 beat Adaptive Biotechnologies' score of -0.38 indicating that Rubius Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adaptive Biotechnologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Rubius Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

82.8% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 95.1% of Rubius Therapeutics shares are held by institutional investors. 3.9% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 55.7% of Rubius Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rubius Therapeutics received 89 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. However, 62.79% of users gave Adaptive Biotechnologies an outperform vote while only 60.93% of users gave Rubius Therapeutics an outperform vote.

CompanyUnderperformOutperform
Adaptive BiotechnologiesOutperform Votes
81
62.79%
Underperform Votes
48
37.21%
Rubius TherapeuticsOutperform Votes
170
60.93%
Underperform Votes
109
39.07%

Summary

Adaptive Biotechnologies beats Rubius Therapeutics on 9 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RUBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Rubius Therapeutics (NASDAQ:RUBY) vs. Its Competitors

TypeRubius TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.09B$3.73B$4.76B$7.59B
Dividend YieldN/A2.16%2.10%2.55%
P/E Ratio-5.719.4722.4822.18
Price / SalesN/A2,671.572,436.86252.56
Price / CashN/A105.5540.35137.79
Price / Book4.865.769.139.96
Net Income-$167.73M$2.48M$95.98M$154.20M
7 Day Performance0.41%-7.33%-5.66%-5.53%
1 Month Performance-22.54%-19.39%-14.89%-12.00%
1 Year Performance78.20%-7.23%9.70%23.42%

Rubius Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TWST
Twist Bioscience
2.1448 of 5 stars
$81.16
-12.2%
$118.25
-45.7%
-20.9%$4.03B$90.10M-28.38525News Coverage
ADPT
Adaptive Biotechnologies
1.9865 of 5 stars
$25.22
-4.0%
$60.33
-139.2%
-45.0%$3.56B$98.38M-18.41622
SWTX
SpringWorks Therapeutics
2.5198 of 5 stars
$66.75
-6.2%
$117.50
-76.0%
+5.9%$3.29B$35M-30.4878
SANA
Sana Biotechnology
1.5699 of 5 stars
$17.04
-7.8%
$38.50
-125.9%
N/A$3.22BN/A-1.83265
RLAY
Relay Therapeutics
2.2848 of 5 stars
$27.89
-5.6%
$51.25
-83.8%
-42.8%$3.01B$82.65M0.002,020
RXRX
Recursion Pharmaceuticals
1.8381 of 5 stars
$17.51
-8.6%
$33.33
-90.4%
N/A$2.96B$3.96M0.00218
VALN
Valneva
1.2682 of 5 stars
$54.30
-15.8%
$36.00
-33.7%
N/A$2.85B$126.02M0.00500Gap Down
KYMR
Kymera Therapeutics
2.1199 of 5 stars
$53.39
-1.4%
$76.43
-43.2%
+4.3%$2.74B$34.03M-31.5975
IOVA
Iovance Biotherapeutics
1.6833 of 5 stars
$16.55
-6.4%
$38.20
-130.8%
-57.4%$2.60BN/A-8.03241
TIL
Instil Bio
2.1164 of 5 stars
$20.00
-9.4%
$30.40
-52.0%
N/A$2.58B$140K0.00150Gap Down
ALLO
Allogene Therapeutics
2.5944 of 5 stars
$17.69
-7.9%
$36.23
-104.8%
-39.4%$2.52BN/A-9.41265Short Interest ↑
IBRX
ImmunityBio
1.8716 of 5 stars
$5.80
-7.2%
$25.00
-331.0%
N/A$2.31B$110K0.00171Upcoming Earnings
Gap Down
BCRX
BioCryst Pharmaceuticals
2.2014 of 5 stars
$11.33
-4.8%
$20.20
-78.3%
+135.5%$2.03B$17.81M-8.92246
RVMD
Revolution Medicines
2.3998 of 5 stars
$25.98
-6.4%
$35.83
-37.9%
-33.8%$1.91B$42.98M-10.96125
DNA
Ginkgo Bioworks
1.825 of 5 stars
$8.75
-16.8%
$14.50
-65.7%
N/A$1.89BN/A0.002,021Analyst Revision
Gap Up
EDIT
Editas Medicine
2.1351 of 5 stars
$27.31
-10.0%
$57.27
-109.7%
-4.8%$1.87B$90.73M-8.43235Gap Up
VCEL
Vericel
1.8548 of 5 stars
$35.96
-0.5%
$53.00
-47.4%
+43.8%$1.68B$124.18M-3,596.00273Insider Selling
NSTG
NanoString Technologies
1.8731 of 5 stars
$36.76
-5.5%
$67.50
-83.6%
-31.4%$1.68B$117.32M-15.07579
CCCC
C4 Therapeutics
2.3579 of 5 stars
$34.17
-3.5%
$48.50
-41.9%
+18.8%$1.66B$33.19M0.0099Analyst Downgrade
ALEC
Alector
2.3714 of 5 stars
$19.44
-6.2%
$40.33
-107.5%
+48.9%$1.58B$21.10M-37.38171
KRYS
Krystal Biotech
2.2464 of 5 stars
$69.20
-2.3%
$115.33
-66.7%
+32.0%$1.54BN/A-25.5375Analyst Report
SRNE
Sorrento Therapeutics
1.9917 of 5 stars
$5.00
-10.2%
$28.67
-473.3%
-29.1%$1.53B$39.99M-4.07502
ATRA
Atara Biotherapeutics
1.8121 of 5 stars
$17.09
-5.4%
$30.33
-77.5%
-24.0%$1.51BN/A-4.72437
INBX
Inhibrx
2.1064 of 5 stars
$36.93
-7.9%
$53.00
-43.5%
+20.8%$1.40B$12.89M-17.8488Analyst Downgrade
Short Interest ↓
News Coverage
CHRS
Coherus BioSciences
2.0648 of 5 stars
$17.74
-1.8%
$25.75
-45.2%
-4.2%$1.36B$475.82M-5.65317
REPL
Replimune Group
2.3865 of 5 stars
$28.00
-3.5%
$55.00
-96.4%
-40.8%$1.31BN/A-14.43152Gap Down
RGNX
REGENXBIO
2.4873 of 5 stars
$30.59
-3.4%
$58.25
-90.4%
-16.0%$1.31B$154.57M-5.92306
ITOS
iTeos Therapeutics
2.1598 of 5 stars
$34.76
-0.9%
$46.25
-33.1%
+30.3%$1.23BN/A119.8662Analyst Downgrade
Insider Selling
Short Interest ↓
IMCR
Immunocore
1.5082 of 5 stars
$28.27
-13.7%
$54.75
-93.7%
N/A$1.22B$38.67M0.002,020News Coverage
Gap Down
SGMO
Sangamo Therapeutics
1.8881 of 5 stars
$8.19
-3.2%
$23.00
-180.8%
-15.3%$1.19B$118.19M-6.45413Insider Selling
ALVR
AlloVir
2.2998 of 5 stars
$17.93
-1.1%
$46.67
-160.3%
-55.2%$1.17B$170K0.0053
OCGN
Ocugen
1.8914 of 5 stars
$5.72
-10.3%
$7.90
-38.1%
+1,881.2%$1.14B$42.62M0.0015
HUMA
Humacyte
2.4917 of 5 stars
$10.32
-6.0%
$17.25
-67.2%
N/A$1.06BN/A0.00N/AGap Down
PCVX
Vaxcyte
1.6065 of 5 stars
$19.56
-4.3%
N/A-34.8%$1.03BN/A-10.9358
CRBU
Caribou Biosciences
1.9848 of 5 stars
$16.94
-6.3%
$30.60
-80.6%
N/A$1.02BN/A0.002,021Analyst Report
Short Interest ↑
Analyst Revision
News Coverage
IMVT
Immunovant
1.9667 of 5 stars
$7.69
-3.1%
$16.00
-108.1%
-84.0%$884.35MN/A-6.0668Positive News
SRRK
Scholar Rock
2.3865 of 5 stars
$25.04
-2.9%
$65.00
-159.6%
-48.4%$879.10M$15.40M-7.34119
IPSC
Century Therapeutics
1.7048 of 5 stars
$15.23
-2.8%
$36.00
-136.4%
N/A$832.18MN/A0.00102
BCAB
BioAtla
2.5333 of 5 stars
$22.57
-1.9%
$65.20
-188.9%
N/A$831.39M$430K0.0036Insider Selling
ICVX
Icosavax
1.825 of 5 stars
$21.04
-3.0%
$48.57
-130.8%
N/A$821.44MN/A0.002,021Gap Up
SOPH
SOPHiA Genetics
1.7 of 5 stars
$12.79
-2.1%
$23.00
-79.8%
N/A$810.09M$28.40M0.00N/AGap Down
OMGA
Omega Therapeutics
1.6681 of 5 stars
$16.73
-6.0%
$29.50
-76.3%
N/A$799.28MN/A0.002,021
VXRT
Vaxart
1.8464 of 5 stars
$6.29
-6.4%
$13.75
-118.6%
-8.1%$789.37M$4.05M-11.6528
TNYA
Tenaya Therapeutics
1.7048 of 5 stars
$19.10
-3.9%
$36.00
-88.5%
N/A$788.47MN/A0.002,021
MGTX
MeiraGTx
2.4514 of 5 stars
$17.45
-6.1%
$26.50
-51.9%
+31.3%$775.64M$15.56M-9.48219Short Interest ↑
GRTS
Gritstone bio
2.3998 of 5 stars
$11.27
-8.3%
$22.33
-98.2%
+312.5%$766.23M$4.04M-8.80169Options Volume
Gap Up
GLUE
Monte Rosa Therapeutics
1.3915 of 5 stars
$16.46
-4.0%
$32.00
-94.4%
N/A$765.49MN/A0.0060Gap Up
AGEN
Agenus
2.1598 of 5 stars
$2.90
-4.1%
$11.00
-279.3%
-16.8%$744.81M$88.17M-24.17359Analyst Upgrade
STRO
Sutro Biopharma
2.0531 of 5 stars
$15.49
-4.8%
$30.83
-99.1%
-0.7%$716.72M$42.72M-5.27192
IMTX
Immatics
1.7 of 5 stars
$11.36
-0.1%
$27.00
-137.7%
+13.7%$714.65M$35.70M0.002,020
This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.